Group 1 - The company primarily focuses on power generation projects located in cities such as Guangzhou, Shenzhen, Maoming, and Zhanjiang [2] - Currently, the company has not yet established any heating-related projects [2] - Investors are encouraged to monitor the company's announcements for updates on new project developments [2]

证券代码：301305 证券简称：朗坤科技 公告编号：2025-074 深圳市朗坤科技股份有限公司 关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保事项概述 近日，公司为旗下三家子公司——北京华融生物科技有限公司、湛江市朗坤 环保能源有限公司、朗坤环保能源（茂名）有限公司，分别向华夏银行股份有限 公司深圳分行申请并开具履约/付款保函，具体信息如下： 北京华融生物科技有限公司：保函编号 SZ3660120250105，金额人民币 464.50 万元； 湛江市朗坤环保能源有限公司：保函编号 SZ3660120250103，金额人民币 1,000.00 万元； 朗坤环保能源（茂名）有限公司：保函编号 SZ3660120250104，金额人民币 1,000.00 万元。 二、被担保人基本情况 （一）被担保人之一 公司名称：北京华融生物科技有限公司 深圳市朗坤科技股份有限公司（以下简称"公司"）分别于 2025 年 4 月 23 日、2025 年 5 月 16 日召开第三届董事会第二十二次会议、第三届监事会第十三 次会议以及 ...

Core Insights - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field, which is seen as a new growth point that can drive industrial structure optimization and economic transformation [1]. Group 1: Current State and Trends - The "2025 China Synthetic Biomanufacturing Industry Development White Paper" was officially released on August 1, highlighting the current state and trends of biomanufacturing [1]. - The report analyzes the global biomanufacturing industry, including key platform facilities and a comparative study between China and the U.S. in the biomanufacturing sector [5][6]. Group 2: Policy Landscape - The report outlines major domestic and international policies affecting biomanufacturing from 2024 to 2025, providing insights into regulatory frameworks that could impact industry growth [5]. Group 3: Industry Map and Applications - A detailed analysis of the biomanufacturing industry chain and key application areas is presented, including sectors such as pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5][6]. - The report identifies ten leading companies in China's biomanufacturing industry, showcasing their roles and contributions [6]. Group 4: Company Strategies - The report includes a summary of the synthetic biology strategies of 15 listed companies, highlighting their respective directions and market positioning [6]. Group 5: Investment and Challenges - An overview of the investment and financing situation in the domestic synthetic biology sector for the period of 2024 to mid-2025 is provided, indicating the financial landscape for potential investors [6]. - The report discusses challenges faced by the biomanufacturing industry in China and offers targeted policy recommendations to address these issues [6].

Investment Rating - The report provides a "Buy" rating for several companies in the power and gas sectors, indicating a positive outlook for their performance [41]. Core Insights - The report highlights the recent adjustments in the value-added tax (VAT) policies for wind and nuclear power, which may impact profitability for operators in these sectors [9][10]. - It notes the competitive pricing results for electricity in Xinjiang and Gansu, with Xinjiang's prices nearing the upper limit of the bidding range, suggesting a favorable environment for renewable energy operators [8]. - The report discusses the decline in global LNG prices, with China's comprehensive LNG import price reaching a four-year low, which could benefit domestic gas companies [12][27]. Summary by Sections 1. Power Sector - Xinjiang's mechanism electricity bidding results show a scale of 36 billion kWh for solar and 185 billion kWh for wind, with prices at 0.235 CNY/kWh and 0.252 CNY/kWh respectively, indicating a competitive market [5][8]. - The VAT policy changes will eliminate the 50% VAT refund for onshore wind from November 1, 2025, while maintaining it for offshore wind until the end of 2027 [9][10]. - Recommendations include focusing on companies like Guodian Power, China Nuclear Power, and Longyuan Power due to their stable growth prospects [11]. 2. Gas Sector - Global gas prices have shown slight declines, with the US Henry Hub price at $2.82/mmBtu, reflecting a 2.90% weekly drop [12][15]. - China's LNG import price has dropped to 2852 CNY/ton, the lowest since mid-2021, driven by lower oil prices affecting long-term contracts [27][29]. - The report suggests a positive outlook for gas companies like Kunlun Energy and New Hope Energy, as cost reductions and economic recovery may enhance profitability [29]. 3. Environmental Sector - The report emphasizes the benefits of debt-for-equity swaps and the increasing stability of returns for green energy operators, recommending companies like China Everbright Environment and Hongcheng Environment [11]. - It highlights the ongoing rise in SAF (Sustainable Aviation Fuel) prices, suggesting investment opportunities in related companies [11]. 4. Key Company Valuations - The report includes a valuation table for key companies, with several rated as "Buy," indicating strong expected performance in the coming years [41].

Investment Rating - The report maintains a positive outlook on the power and gas sectors, highlighting potential investment opportunities in renewable energy and gas companies [3][12]. Core Insights - The report emphasizes the recent adjustments in value-added tax policies for wind and nuclear power, which may impact profitability in the short to medium term [10][11]. - It notes the significant drop in LNG import prices, reaching a four-year low, which could benefit gas companies and consumers [13][29]. - The report suggests that the competitive bidding results for electricity prices in Xinjiang and Gansu indicate varying strategies among renewable energy operators, which could lead to improved profit margins [9][12]. Summary by Sections 1. Power Sector - Xinjiang's competitive bidding results show a mechanism electricity price of 0.252 CNY/kWh for wind power, close to the upper limit, while Gansu's price is 0.1954 CNY/kWh, near the lower limit [5][9]. - The adjustment of the value-added tax policy for onshore wind power, effective November 1, 2025, will eliminate the 50% refund policy, while offshore wind will retain it until the end of 2027 [10][11]. - Recommendations include focusing on companies like Guodian Power, Sichuan Investment Energy, and China Nuclear Power due to their stable growth prospects [12]. 2. Gas Sector - The report highlights a slight decline in global gas prices, with the US Henry Hub price at $2.82/mmBtu, down 2.90% week-on-week, and LNG import prices in China dropping to 2852 CNY/ton, the lowest since mid-2021 [13][29]. - It suggests that the cost reduction in upstream resources and the recovery of the macro economy will benefit Hong Kong gas companies like Kunlun Energy and New Hope Energy [31]. - The report anticipates that the LNG prices may stabilize as demand increases with the onset of colder weather [29][31]. 3. Weekly Market Review - The public utility, power, gas, and environmental protection sectors outperformed the CSI 300 index during the week of October 13-17, 2025 [35]. - The report notes that the power equipment sector lagged behind the index, indicating potential investment opportunities in other sectors [35]. 4. Company and Industry Dynamics - The report discusses the upcoming competitive bidding for renewable energy projects in Anhui, with a bidding range set between 0.2 CNY/kWh and 0.3844 CNY/kWh [41][42]. - It highlights the performance of major companies, such as China General Nuclear Power and Longyuan Power, which reported varying results in their electricity generation [43][44].

Core Viewpoint - Longkun Technology (301305.SZ) announced the completion of a share reduction plan by several shareholders, indicating a strategic shift in ownership [1] Summary by Relevant Sections - **Shareholder Actions** - Shareholders Huadi Guangda, Qiandeng Huadi, Liumai Zijiang, and Zijiang Kaiyuan have cumulatively reduced their holdings by 2.1137 million shares [1] - This reduction represents 0.8762% of the company's total share capital [1] - **Reduction Plan Details** - The share reduction was executed through block trades and centralized bidding during the designated reduction period [1] - The reduction plan has now reached its deadline, concluding the specified timeframe for these transactions [1]

证券代码：301305 证券简称：朗坤科技 公告编号：2025-073 深圳市朗坤科技股份有限公司 关于股东及其一致行动人减持公司股份时间届满暨减持结 果的公告 一、股东减持情况 股东深圳华迪光大股权投资基金（有限合伙）、广东千灯华迪股权投资企业 （有限合伙）、广州盛隆投资合伙企业（有限合伙）、广州六脉资江股权投资合伙 企业（有限合伙）、贵州沛硕股权投资合伙企业（有限合伙）、广州资江凯源股权 投资合伙企业（有限合伙）和贵州享硕股权投资合伙企业（有限合伙）保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 1、减持股份来源：公司首次公开发行前取得的股份 深圳市朗坤科技股份有限公司（以下简称"公司"）股东深圳华迪光大股权 投资基金（有限合伙）（以下简称"华迪光大"）、广东千灯华迪股权投资企业（有 限合伙）（以下简称"千灯华迪"）、广州盛隆投资合伙企业（有限合伙）（以下简 称"广州盛隆"）、广州六脉资江股权投资合伙企业（有限合伙）（以下简称"六 脉资江"）、贵州沛硕股权投资合伙企业（有限合伙）（以下简称"贵州沛硕"） ...

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field that disrupts traditional production methods, presenting it as a new growth point for optimizing industrial structures and transforming economic models. The release of the "2025 China Synthetic Biomanufacturing Industry Development White Paper" highlights the current state, trends, and challenges of the biomanufacturing industry in China [1]. Group 1: Current State and Trends - The white paper outlines the development status and trends of biomanufacturing, analyzing the global landscape and key platform facilities [5]. - It compares the biomanufacturing sectors of China and the United States, identifying competitive advantages and areas for improvement [5]. - Future development trends in biomanufacturing are discussed, indicating a shift towards more integrated and innovative approaches [5]. Group 2: Policy Landscape - The report reviews major policies affecting biomanufacturing both domestically and internationally, providing insights into regulatory frameworks that shape the industry [5]. - It categorizes foreign and domestic policies, highlighting their implications for the growth of the biomanufacturing sector [5]. Group 3: Industry Map and Applications - A comprehensive map of the Chinese biomanufacturing industry is presented, detailing key players and their roles [5]. - The report identifies critical application areas for biomanufacturing, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5]. Group 4: Key Enterprises and Investment Landscape - The white paper lists the top 10 leading enterprises in China's biomanufacturing sector, showcasing their contributions and market positions [6]. - It also summarizes the strategic directions of 15 publicly listed companies in synthetic biology, along with their investment and development strategies [6]. Group 5: Challenges and Recommendations - The report discusses the challenges faced by the biomanufacturing industry in China, including technological, regulatory, and market-related issues [6]. - Targeted policy recommendations are provided to address these challenges and promote sustainable growth in the biomanufacturing sector [6].

Group 1 - The company is currently in the trial production phase of its first phase project, which involves 260 tons of production capacity [2] - The production workshop is progressing in an orderly manner, indicating that operations are on track [2] - Investors are encouraged to monitor the company's future announcements for updates on the related business progress [2]

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field, which is seen as a new growth point that can drive industrial structure optimization and economic transformation. The release of the "2025 China Synthetic Biomanufacturing Industry Development White Paper" highlights the current state, trends, and challenges of the biomanufacturing industry in China [1]. Group 1: Current State and Trends - The white paper provides an overview of the global biomanufacturing industry, including its development status and trends [5]. - It compares the biomanufacturing sectors of China and the United States, highlighting competitive dynamics [5]. - Future development trends in biomanufacturing are discussed, indicating potential growth areas [5]. Group 2: Policy Landscape - The report outlines major policies affecting biomanufacturing both domestically and internationally for the years 2024-2025 [5]. - It details foreign biomanufacturing industry policies and their implications for the sector [5]. - Domestic policies related to biomanufacturing are also analyzed, providing insights into regulatory frameworks [5]. Group 3: Industry Map and Applications - The white paper presents a comprehensive map of the Chinese biomanufacturing industry, identifying key players and their roles [5]. - It analyzes the biomanufacturing industry chain and key application areas, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5][6]. - Specific applications of biomanufacturing in various sectors are highlighted, showcasing its versatility and potential impact [5]. Group 4: Key Enterprises and Investment Landscape - The report identifies ten leading enterprises in the Chinese biomanufacturing industry, providing insights into their operations and market positions [6]. - It summarizes the strategic directions of 15 listed companies in synthetic biology, indicating their focus areas and growth strategies [6]. - The investment landscape for synthetic biology in China is examined, detailing funding trends and opportunities from 2024 to mid-2025 [6]. Group 5: Challenges and Recommendations - The white paper discusses the challenges faced by the biomanufacturing industry in China, including technological, regulatory, and market-related issues [6]. - It offers targeted policy recommendations to address these challenges, aiming to support the sustainable development of the biomanufacturing sector [6].